Figure 3.

Efficacy evaluation of OralGem’s MTR daily administration in a mouse model of lung metastasis. (A) IC₅₀ values of gemcitabine and OralGem on B16-F10 cell line. Experiments were performed in triplicates, and statistical analysis was performed via t-test (n = 3). (B) The efficacy of MTD and MTR chemotherapy was evaluated stereoscopically. Μale C57BL/6 mice were injected via the tail vein with B16-F10 cells (5 x10⁵ cells). Two days after cell inoculation, mice were divided randomly into 3 groups. The MTD group (n = 7) received i.p. gemcitabine (120 mg/kg) for 3 times in a period of 9 days. The MTR group (n = 7) received per os OralGem (6 mg/kg) 8 times in a period of 9 days. The control group (n = 8) received per os 0.5% CMC for 8 times in a period of 9 days (set of experiments = 2). (C) Average tumor diameter is shown. Data are mean ± SD. Statistical analysis was performed by Student’s t-test; ** p < 0.01 and **** p < 0.0001. (D) Hematoxylin and eosin (H&E) staining of the big lung lobe as indicated (1× magnification stereoscope).